EMEA-001849-PIP02-15-M04

Adopted

First published: 27/03/2023
EMA/709533/2021

Invented name	Bavencio
Active substance	avelumab
Therapeutic area	Oncology
Decision number	P/0546/2021
PIP number	EMEA-001849-PIP02-15-M04
Pharmaceutical form(s)	Concentrate for solution for infusion
Condition(s) / indication(s)	Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) Treatment of malignant neoplasms of lymphoid tissue Treatment of malignant neoplasms of the central nervous system
Route(s) of administration	Intravenous use
Contact for public enquiries	Merck Healthcare KGaA Email: service@merckgroup.com Tel. +49 6151725200
Decision type	PM: decision on the application for modification of an agreed PIP